Tonix Pharmaceuticals Holding Corp (NAS:TNXP)
$ 0.1883 -0.0005 (-0.26%) Market Cap: 35.19 Mil Enterprise Value: 15.65 Mil PE Ratio: 0 PB Ratio: 0.39 GF Score: 31/100

Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference Transcript

Feb 18, 2020 / 06:30PM GMT
Seth Lederman
Tonix Pharmaceuticals Holding Corp - CEO and Chairman

Thank you all for coming. I am Seth Lederman, the CEO of Tonix Pharmaceuticals, and we're on NASDAQ. So, this is our standard Safe Harbor statement. I will be making forward-looking statements. Tonix is a NASDAQ company. We recently did a financing last week. We just closed on a financing, it's a very exciting time for our company. Our lead program is a treatment for Fibromyalgia. That's in Phase-3 development and it's a very big year for us in this program. The Phase-3 program will have an interim analysis in the third quarter of this year, and we expect top line data in the first half of 2021.

So, I'm going to spend most of the time talking about our lead program in fibromyalgia, but I also want to take you through our pipeline. This is the three main programs that we have in central nervous system development. And the first one TNX-102 SL, we are pursuing for three different indications, fibromyalgia, which is in Phase-3 that I mentioned, bedtime treatment for agitation in Alzheimer's, which we have in IND, but have not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot